We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Symptomatic cartilage defects in the knee
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Osteoarthritis is a condition that affects the bone and cartilage (the protective surface that allows your joints to move smoothly). Symptoms include joint damage, pain and loss of mobility, and in the longer term most patients need a total joint replacement. Cell therapy is a novel method of treating patients with damaged cartilage and bone, but it is not yet known which type of cells would do this best. Patients with cartilage damage have been treated with cartilage cells (chondrocytes) for over 10 years and patients with bone fractures that fail to heal properly are treated with stem cells from their bone marrow. In all, over 400 patients to date have been treated with their own cells for cartilage and/or bone repair. These patients are treated with cells that have been grown in specialist facilities available on the hospital site from small samples of their own cartilage or bone marrow. Since this technique uses the patients' own cells (called autologous), the cells are not likely to cause an immune reaction. The aim of this study is to see whether stem cells from bone marrow will be able to repair the damage to joints better than cartilage cells, or if the two cell types are better when used in combination.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
You can take part if:
You may not be able to take part if:
1. English is not the first language of the patient2. Likely to show contraindications to autologous cell therapy: 2.1. Osteoarthritis2.2. Inflammatory arthritis2.3. Previous or current malignant tumour2.4. Therapy with steroids or methotrexate2.5. Bleeding tendency or known anaphylaxis to any product used in chondrocyte preparation3. Low probability of compliance with physiotherapy or follow-up, including a major life threatening condition4. A defect of greater than 20cm2 in total area5. The patient is shown to be positive for serology tests required by the cell provider. This includes: 5.1. HIV5.2. Hepatitis B and C5.3. Syphilis5.4. Human T cell lymphotrophic virus (HTLV) I & II6. Pregnancy or lactation7. Exclusion criteria (5) and (6) will not be confirmed until after written informed consent is obtained
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Dr
Naomi
Dugard
+44 (0)1691 404139
naomi.dugard@nhs.net
The study is sponsored by Robert Jones and Agnes Hunt Orthopaedic Hospital (UK) and funded by Arthritis Research UK ref: 18480.
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Or CPMS 12383
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
